Oral drug for di­a­bet­ic retinopa­thy flunks PhII, but biotech wants to go in­to PhI­II with new end­point

When you’re try­ing to de­vel­op the first oral treat­ment for di­a­bet­ic pa­tients with eye dis­ease, a Phase II flop need not be the end of the road — at least ac­cord­ing to Ocuphire Phar­ma.

The Farm­ing­ton Hills, MI-based biotech re­port­ed that its drug has missed the pri­ma­ry end­point in the ZE­TA-1 tri­al for di­a­bet­ic retinopa­thy, fail­ing to help enough pa­tients achieve a two-step im­prove­ment in the study eye on the di­a­bet­ic retinopa­thy sever­i­ty scale (DRSS) at week 24.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER